| CAR T cells in solid tumors: challenges and opportunities F Marofi, R Motavalli, VA Safonov, L Thangavelu, AV Yumashev, ... Stem cell research & therapy 12, 1-16, 2021 | 439 | 2021 |
| Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders A Markov, L Thangavelu, S Aravindhan, AO Zekiy, M Jarahian, ... Stem cell research & therapy 12, 1-30, 2021 | 323 | 2021 |
| A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine S Moghadasi, M Elveny, HS Rahman, W Suksatan, AT Jalil, ... Journal of translational medicine 19, 1-21, 2021 | 236 | 2021 |
| CAR‐NK cell in cancer immunotherapy; A promising frontier F Marofi, OF Abdul‐Rasheed, HS Rahman, HS Budi, AT Jalil, ... Cancer Science 112 (9), 3427-3436, 2021 | 192 | 2021 |
| Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients F Marofi, HS Rahman, ZMJ Al-Obaidi, AT Jalil, WK Abdelbasset, ... Stem Cell Research & Therapy 12, 1-23, 2021 | 176 | 2021 |
| CTLA-4: From mechanism to autoimmune therapy A Hosseini, T Gharibi, F Marofi, Z Babaloo, B Baradaran International immunopharmacology 80, 106221, 2020 | 170 | 2020 |
| Stem cell therapy in Asherman syndrome and thin endometrium: Stem cell-based therapy R Azizi, L Aghebati-Maleki, M Nouri, F Marofi, S Negargar, M Yousefi Biomedicine & Pharmacotherapy 102, 333-343, 2018 | 168 | 2018 |
| Mesenchymal stromal/stem cells: a new era in the cell-based targeted gene therapy of cancer F Marofi, G Vahedi, A Biglari, A Esmaeilzadeh, SS Athari Frontiers in immunology 8, 311773, 2017 | 123 | 2017 |
| Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities A Hassanzadeh, HS Rahman, A Markov, JJ Endjun, AO Zekiy, ... Stem cell research & therapy 12 (1), 297, 2021 | 92 | 2021 |
| A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies E Razeghian, MKM Nasution, HS Rahman, ZR Gardanova, ... Stem cell research & therapy 12, 1-17, 2021 | 90 | 2021 |
| Nanocurcumin restores aberrant miRNA expression profile in multiple sclerosis, randomized, double‐blind, placebo‐controlled trial S Dolati, L Aghebati‐Maleki, M Ahmadi, F Marofi, Z Babaloo, H Ayramloo, ... Journal of cellular physiology 233 (7), 5222-5230, 2018 | 83 | 2018 |
| Targeting STAT3 in cancer and autoimmune diseases T Gharibi, Z Babaloo, A Hosseini, M Abdollahpour-Alitappeh, V Hashemi, ... European journal of pharmacology 878, 173107, 2020 | 80 | 2020 |
| Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing inflammatory mediators S Dolati, M Ahmadi, L Aghebti-Maleki, A Nikmaram, F Marofi, R Rikhtegar, ... Pharmacological reports 70 (6), 1158-1167, 2018 | 79 | 2018 |
| Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases A Hosseini, T Gharibi, F Marofi, M Javadian, Z Babaloo, B Baradaran Journal of Cellular Physiology 235 (9), 5903-5924, 2020 | 77 | 2020 |
| T cell subsets in peripheral blood of women with recurrent implantation failure M Ghaebi, S Abdolmohammadi-Vahid, M Ahmadi, S Eghbal-Fard, ... Journal of reproductive immunology 131, 21-29, 2019 | 60 | 2019 |
| Natural killer cell–based immunotherapy: from transplantation toward targeting cancer stem cells H Dianat‐Moghadam, M Rokni, F Marofi, Y Panahi, M Yousefi Journal of cellular physiology 234 (1), 259-273, 2019 | 54 | 2019 |
| Dysregulated network of miRNAs involved in the pathogenesis of multiple sclerosis S Dolati, F Marofi, Z Babaloo, L Aghebati-Maleki, L Roshangar, M Ahmadi, ... Biomedicine & Pharmacotherapy 104, 280-290, 2018 | 53 | 2018 |
| CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies F Marofi, MM Saleh, HS Rahman, W Suksatan, ME Al-Gazally, ... Stem cell research & therapy 12 (1), 374, 2021 | 48 | 2021 |
| miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4 MRMH Azar, H Aghazadeh, HN Mohammed, MRS Sara, A Hosseini, ... International immunopharmacology 92, 107355, 2021 | 42 | 2021 |
| Gene expression of TWIST1 and ZBTB16 is regulated by methylation modifications during the osteoblastic differentiation of mesenchymal stem cells F Marofi, G Vahedi, S Solali, M Alivand, S Salarinasab, ... Journal of cellular physiology 234 (5), 6230-6243, 2019 | 42 | 2019 |
Shomali,NavidPhD in Clinical Immunology, Tabriz University of Medical Sciences, Tabriz, IranVerified email at tbzmed.ac.ir
